A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

This study is testing whether a drug called orelabrutinib — which blocks a protein involved in immune cell activity — can slow disability progression in people with primary progressive multiple sclerosis (PPMS), a form of MS that gradually worsens without relapses. **You may be eligible if...** - You are 18 to 60 years old - You have been diagnosed with primary progressive MS (PPMS) based on current medical criteria - Your disability has been documented as worsening in the past 24 months - Your disability score (EDSS) is between 3.0 and 6.5 **You may NOT be eligible if...** - You have a different form of MS (relapsing-remitting or secondary progressive) - You have another immune or neurological disease - You have had a malignancy in the past 5 years - You are on blood thinners or antiplatelet drugs - You have had alcohol or drug abuse issues in the past year - You have had a live vaccine within the past month Talk to your doctor to see if this trial is right for you.